ContinueWhite button caret.


Explore the treatment possibilities for MAC lung disease with this Culture Conversion Experience in augmented reality—right here on your mobile device

MAC=Mycobacterium avium complex.

Please refresh this page to enable camera and/or motion access.

Ensure camera and motion access is allowed in app settings.

Press button to show MAC infection in lungs

Organisms are representational and not to scale

MAC lung disease is a tenacious bacterial infection1

mac animation gif

of MAC lung disease patients experienced radiographic deterioration over a median follow-up period of 5 years1

Which initial treatments do you use for MAC lung disease?
Choose 3

Though standard therapies work for many patients, they don't always work, and the infection remains2,3

Outline of AR PersonOutline of AR PersonOutline of AR Person
Outline of AR PersonOutline of AR PersonOutline of AR Person

But there may be a way to move refractory patients from culture positive to culture negative

See how adding ARIKAYCE may help refractory MAC patients achieve culture conversion after first-line therapy fails1


LIMITED POPULATION: ARIKAYCE® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.

This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

plus icon only


This site is for US audiences only. © 2023 Insmed Incorporated. All Rights Reserved. Insmed, ARIKAYCE, Arikares, and PULMOVANCE are trademarks of Insmed Incorporated. All other trademarks are property of their respective owner. PP-ARIK-US-02001